Olive oil intake and liver fat in adults with fatty liver disease
Tests extra virgin olive oil amounts in adults with fatty liver disease who are overweight.
Plain-language title generated from the registry record
Registry title: EVOO and Metabolic Liver Health in MASLD
Key facts
- Where
- Castellana Grotte, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07412444, who can take part
Where in Italy
- UOS Data ScienceCastellana Grotte, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- Trial code
- NCT07412444
- Record updated
- 6 May 2026
- Original description
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and other cardio-metabolic risk factors. Lifestyle modification, particularly through the Mediterranean Diet, is the first-line intervention, and extra virgin olive oil is a key component thanks to its monounsaturated fatty acids and bioactive compounds with anti-inflammatory and antioxidant effects.Read full original descriptionShow less
Evaluation of the Effects of Extra Virgin Olive Oil Consumption on Hepatic Steatosis Parameters and on Glucose and Lipid Metabolism in Subjects With MASLD.
MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and other cardio-metabolic risk factors. Lifestyle modification, particularly through the Mediterranean Diet, is the first-line intervention, and extra virgin olive oil is a key component thanks to its monounsaturated fatty acids and bioactive compounds with anti-inflammatory and antioxidant effects.
Several studies indicate that extra virgin olive oil supplementation, especially within a Mediterranean Diet pattern, reduces hepatic steatosis, improves inflammation, oxidative stress, and glucose and lipid profiles, and may promote weight loss and reduction of fat mass, also through potential effects on the gut microbiota. EFSA recognizes protective effects with a daily intake of at least 20 g of extra virgin olive oil, but it is still unclear whether this amount is optimal for individuals with MASLD, particularly those who are overweight or obese
Inclusion: Subjects with 20 ≤ BMI < 30; Age range between 18 and 65 years, both sexes; Diagnosis of hepatic steatosis, made on the basis of recognized criteria (FibroScan [CAP (controlled attenuation parameter) > 288 dB/m], FLI).
Exclusion: Presence of any condition that may influence the occurrence of steatosis other than the conditions representing inclusion criteria; Severe medical conditions that may compromise participation in the trial; Subjects with BMI < 20 and BMI > 30; Pregnancy or breastfeeding; Individuals following a special diet.